Lung cancer after neoadjuvant therapy - Revision history

Michael at 18:46, 5 May 2025

2025-05-05T18:46:49Z

← Older revision		Revision as of 18:46, 5 May 2025
Line 29:		Line 29:
	==See also==		==See also==
	*[[Neoadjuvant therapy]].		*[[Neoadjuvant therapy]].
			*[[Residual cancer burden index]].

	==References==		==References==

Michael at 20:11, 21 February 2024

2024-02-21T20:11:05Z

← Older revision		Revision as of 20:11, 21 February 2024
Line 15:		Line 15:
	At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16).		At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16).

	The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour ~~exceeds~~ the cut-off (<=10%) for ~~"Major Pathologic Response"~~.[1]		The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour EXCEEDS the cut-off value (<=10%); thus, the specimen is NEGATIVE for a major pathologic response.[1]

	1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005		1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
Line 22:		Line 22:
	===At cut-off value for major pathology response===		===At cut-off value for major pathology response===
	<pre>		<pre>
	The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for ~~'Major Pathologic Response'~~.[1] Additional sections of the tumour bed are negative; thus, a ~~'Major Pathologic Response'~~ is favoured.		The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for major pathologic response.[1] Additional sections of the tumour bed are negative; thus, a major pathologic response is favoured.

	1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005		1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005

Michael at 20:06, 21 February 2024

2024-02-21T20:06:07Z

← Older revision		Revision as of 20:06, 21 February 2024
Line 2:		Line 2:

	==Major pathologic response==		==Major pathologic response==
	:<math>V ={ {T} \over {B} } \times 100\%</math>		:<math>V ={ {T} \over {B} } \times 100 \%</math>

	Where:		Where:

Michael at 20:05, 21 February 2024

2024-02-21T20:05:48Z

← Older revision		Revision as of 20:05, 21 February 2024
Line 2:		Line 2:

	==Major pathologic response==		==Major pathologic response==
	:<math>V ={ {T} \over {B} } \times 100%</math>		:<math>V ={ {T} \over {B} } \times 100\%</math>

	Where:		Where:

Michael at 20:04, 21 February 2024

2024-02-21T20:04:12Z

← Older revision		Revision as of 20:04, 21 February 2024
Line 2:		Line 2:

	==Major pathologic response==		==Major pathologic response==
	:<math>V = T/B</math>		:<math>V ={ {T} \over {B} } \times 100%</math>

	Where:		Where:
			:V = percent viable tumour.
	:T = tumour area.		:T = tumour area.
	:B = tumour bed area.		:B = tumour bed area.
	~~:V = viable tumour.~~

	Major pathologic response is defined as: V <=10%.		Major pathologic response is defined as: V <=10%.

Michael at 19:53, 21 February 2024

2024-02-21T19:53:46Z

← Older revision		Revision as of 19:53, 21 February 2024
Line 1:		Line 1:
	'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal \|authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y \|title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy \|journal=J Thorac Oncol \|volume=15 \|issue=5 \|pages=709–740 \|date=May 2020 \|pmid=32004713 \|pmc=8173999 \|doi=10.1016/j.jtho.2020.01.005 \|url=}}</ref>		'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal \|authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y \|title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy \|journal=J Thorac Oncol \|volume=15 \|issue=5 \|pages=709–740 \|date=May 2020 \|pmid=32004713 \|pmc=8173999 \|doi=10.1016/j.jtho.2020.01.005 \|url=}}</ref>

			==Major pathologic response==
			:<math>V = T/B</math>

			Where:
			:T = tumour area.
			:B = tumour bed area.
			:V = viable tumour.

			Major pathologic response is defined as: V <=10%.
	==Sign out==		==Sign out==
	<pre>		<pre>
Line 11:		Line 19:
	</pre>		</pre>

	===At cut-off value for ~~Major Pathology Response~~===		===At cut-off value for major pathology response===
	<pre>		<pre>
	The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for 'Major Pathologic Response'.[1] Additional sections of the tumour bed are negative; thus, a 'Major Pathologic Response' is favoured.		The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for 'Major Pathologic Response'.[1] Additional sections of the tumour bed are negative; thus, a 'Major Pathologic Response' is favoured.

Michael: +so

2024-02-21T19:44:57Z

+so

← Older revision		Revision as of 19:44, 21 February 2024
Line 1:		Line 1:
	'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal \|authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y \|title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy \|journal=J Thorac Oncol \|volume=15 \|issue=5 \|pages=709–740 \|date=May 2020 \|pmid=32004713 \|pmc=8173999 \|doi=10.1016/j.jtho.2020.01.005 \|url=}}</ref>		'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal \|authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y \|title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy \|journal=J Thorac Oncol \|volume=15 \|issue=5 \|pages=709–740 \|date=May 2020 \|pmid=32004713 \|pmc=8173999 \|doi=10.1016/j.jtho.2020.01.005 \|url=}}</ref>


			==Sign out==
			<pre>
			At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16).

			The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour exceeds the cut-off (<=10%) for "Major Pathologic Response".[1]

			1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
			</pre>

			===At cut-off value for Major Pathology Response===
			<pre>
			The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for 'Major Pathologic Response'.[1] Additional sections of the tumour bed are negative; thus, a 'Major Pathologic Response' is favoured.

			1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
			</pre>

	==See also==		==See also==

Michael at 19:35, 21 February 2024

2024-02-21T19:35:24Z

← Older revision		Revision as of 19:35, 21 February 2024
Line 7:		Line 7:
	{{Reflist\|1}}		{{Reflist\|1}}

	[[Category:~~Lung~~ pathology]]		[[Category:Pulmonary pathology]]

Michael: create

2024-02-21T19:35:12Z

create

New page

'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal |authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y |title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy |journal=J Thorac Oncol |volume=15 |issue=5 |pages=709–740 |date=May 2020 |pmid=32004713 |pmc=8173999 |doi=10.1016/j.jtho.2020.01.005 |url=}}</ref>

==See also==
*[[Neoadjuvant therapy]].

==References==
{{Reflist|1}}

[[Category:Lung pathology]]